Nat Commun: The study defined new immune characteristics in patients with PD-L1-negative ER-positive breast cancer.

Responses to immunotherapy are uncommon in estrogen-positive breast cancers and so far there are no predictive markers.
randomized Phase II study defined the safety and response rate of checkpoint inhibitors treating ER-positive breast cancer patients as the primary endpoint.
secondary and exploratory endpoints include PD-L1 regulation and T-cell immune signaling.
results, 34 patients received volinotha, tymoxifen and pembrolizumab, which were not overly toxic after advances in the previous five transfer treatments.
objective response was 4% and the clinical benefit rate (CR-PR-SD-6 m) was 19%.
T-cell failure (CD8 plus PD-1/CTLA-4 plus) and therapeutic regulatory T-cell failure (CD4 plus Foxp3 plus/CTLA-4 plus) were visible in the tumor or blood of 5/5 clinically benefited patients, but only 1 case was non-reactive.
tumor lymphocyte immersion rate was 0.17%.
only two non-reactive people had PD-L1 expression greater than 1%.
, the data defined new immune characteristics in patients with PD-L1-negative ER-positive breast cancer who were more likely to benefit from immunosupers and histogen deacetylase inhibition.
.